Bridge Biotherapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Bridge Biotherapeutics, Inc. - overview
Established
2015
Location
Seongnam, Gyeonggi-do, South Korea
Primary Industry
Biotechnology
About
Based in Seongnam-si, South Korea, Bridge Biotherapeutics, Inc. is an NRDO (No Research Development Only) biopharmaceuticals company that focuses on the development of new drugs and drug platforms for respiratory, inflammation, and oncology diseases. In 2015, Bridge Biotherapeutics, Inc. acquired an in-licensing agreement for BBT-401, a drug candidate for ulcerative colitis.
In 2016, Bridge Biotherapeutics, Inc. established its subsidiary in the US. In 2019, Bridge Biotherapeutics, Inc. was listed on the KOSDAQ.
The current CEO of the company is James Jungkue Lee. Bridge Biotherapeutics, Inc. develops several pipelines for respiratory, inflammation, and oncology diseases. Some of the main pipelines include BBT-877, autotaxin inhibitor, BBT-401, Pelino-1 inhibitor, and BBT-176, EGFR Tyrosine Kinase inhibitor.
All of the three pipelines have passed pre-clinical study.
Current Investors
SV Investment Partners, WOORI Venture Partners, IMM Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.bridgebiorx.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.